Attention www.globalkeysolutions.net is now www.keypedia.com, read the full press release here.
KeyPedia LogoKeyPedia Icon
  1. Home
  2. /
  3. Records
  4. /
  5. Eir
  6. /
  7. Siegfried USA, LLC
EIR
•Siegfried USA, LLC•September 27, 2023

Siegfried USA, LLC – FDA EIR, Sep 27, 2023

Record Details

An FDA inspection of Siegfried USA, LLC in Pennsville, NJ, was conducted from September 18 to September 27, 2023. This was an unannounced surveillance inspection focusing on Good Manufacturing Practices (GMP) for Active Pharmaceutical Ingredients (API) and a Pre-Approval Inspection (PAI) for a specific ANDA application. The regulatory framework included compliance programs for Pre-Approval Inspections, API Process Inspections, Animal Drug Manufacturing Inspections, and Drug Manufacturing Inspections.

The inspection identified one significant observation, documented on a Form FDA 483, related to the laboratory control system. The firm failed to ensure the suitability and verification of test methods due to improper storage of reference standards. Specifically, primary reference standards, resolution solutions, and reagents were stored in a Quality Control laboratory refrigerator outside the manufacturer’s recommended temperature range (2-8 °C) since November 2022. No investigations were initiated to assess the impact of this temperature excursion on the purity and integrity of these standards, which were subsequently used to release multiple drug products, including Phenobarbital Sodium and Buprenorphine. Furthermore, the firm lacked established written procedures for the quality oversight and maintenance of laboratory refrigeration units.

Siegfried USA, LLC's Senior Vice President and General Manager committed to providing a written response to these observations within 15 business days. Despite the observation, an approval recommendation was issued for the PAI portion of the inspection regarding the ANDA application.

Company
Siegfried USA, LLC
Inspection date
September 27, 2023
Product type
drugs
Office
Center for Drug Evaluation and Research
People
  • Stephen Lijoi (recipient)
  • Craig D. Zagata (Investigator)
  • Samuel Midili (company_representative)
  • William Graham (company_representative)
  • Eric Hoeschel (company_representative)
View Company Profile

ID · 9583d279-5c95-422c-b41f-10e04ae0f31a

Violation Codes1
21 CFR 211

Full citation text and observation details available on the Dashboard.

Other documents for Siegfried USA, LLC
  • 483 - 2023-09-27September 27, 2023
  • EIR - 2018-12-19December 19, 2018

Your cart

Your cart is empty.

Browse public document pages and click Buy this document. We'll ask for your email at checkout, no account needed up front.

Browse documents

Discuss this record with AI

KeyPedia

ChatGPT

Claude

Perplexity

Grok

Copilot

Document or profile

One record shows the event. A profile shows the pattern.

Buy this document for the source file and details behind this single event.

Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.

Explore Siegfried USA, LLC
KeyPedia
Regulatory Data Transformed
Stay in the loop

KRA score changes, company updates and news. About monthly, unsubscribe anytime.

Contact
New York Office:
370 Jay Street 7th Floor
Brooklyn, NY 11201
Scranton Office:
Scranton Enterprise Center, Suite 217
201 Lackawanna Avenue
Scranton, PA, 18503
🇺🇸+1 917-789-5099
🇪🇺+48 532-447-507
info@keypedia.com
Quick Links
HomePlatform OverviewMedia
KeyPedia™ Lite
Browse HubDatabase DirectoryRecordsCompaniesOfficesPeopleCareersAbout UsFounding TeamMeet Our ExpertsPartners
Legal & Ethics
Privacy PolicyTerms of ServiceOur Values & MissionCode of Ethics & AI Policy
©2026 KeyPedia™ | Global Key Solutions Corp. All rights reserved.